Penn Virginia Corp (PVA) 0.15 $PVA pSivida Corp.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Penn Virginia Corp (PVA) 0.15 $PVA

pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Thu Sep 01, 9:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the fourth quarter and fiscal year 2016 will be released after the market close on Monday, September 12, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Announces 13 New Patents Issued or Allowed
GlobeNewswire - Mon Aug 29, 9:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced the addition of 13 U.S. and foreign issued patents and allowed applications since the start of 2016. This brings the total number of patents issued and applications allowed in the Company's intellectual property portfolio to 42 in the U.S. and 191 in foreign jurisdictions. An additional 108 applications are pending in the U.S. and foreign jurisdictions.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

Topline Results from First Phase 3 Trial of pSivida's Medidur(TM) Presented at ASRS Annual Meeting
GlobeNewswire - Mon Aug 15, 8:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC and the principal investigator on the first of pSivida's two Phase 3 trials of Medidur for recurrent non-infectious uveitis affecting the posterior segment of the eye, presented the topline results from the trial through its six-month primary endpoint and through 12 months of follow-up. Dr. Jaffe's presentation, "A Randomized, Masked, Controlled, Safety and Efficacy Study of an Injectable Fluocinolone Acetonide (FA) Intravitreal Insert in Non-Infectious Uveitis" took place at the Inflammatory and Infectious Disease session of the American Society of Retinal Specialists Annual Meeting, on Sunday, August 14, in San Francisco.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

Primary Endpoint Met in pSivida's Utilization Study of New Medidur(TM) Inserter with Smaller Diameter Needle
GlobeNewswire - Tue Aug 09, 9:16AM CDT
pSivida Corp. (NASDAQ SDV); (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that its utilization study of its new, proprietary 27-gauge inserter for Medidur for posterior uveitis has met its primary endpoint. In the study, 66 percent of injections using the new 27-gauge inserter achieved a satisfactory rating of "Routine," "Easy" or "Very Easy" while only 46 percent of injections utilizing the earlier, larger 25-gauge inserter used in the first Medidur Phase 3 trial met that standard. The results of this study will form part of pSivida's planned U.S. New Drug Application and application for EU marketing authorization for Medidur for posterior uveitis.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer
GlobeNewswire - Wed Aug 03, 7:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, has named Dario A. Paggiarino, M.D., to the newly-created position of vice president, chief medical officer. Dr. Paggiarino brings more than 25 years' experience in the pharmaceutical industry. His addition strengthens pSivida's clinical development program, following the consolidation of all of its research and development in the U.S.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
GlobeNewswire - Mon Aug 01, 6:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America's leading specialty hospital devoted to orthopedics and rheumatology, announce the opening of an investigational new drug application (IND) to begin an investigator-sponsored clinical study of a sustained-release implant to treat severe osteoarthritis (OA) of the knee. The implant is designed to provide long-term pain relief for severe knee OA, which is anticipated to delay the need for knee replacement surgery.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
GlobeNewswire - Thu May 05, 3:01PM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31, 2016.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
GlobeNewswire - Wed May 04, 7:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, president and CEO, will present "Changing the Treatment Paradigm through Innovative Drug Delivery" at the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) on Sunday, May 8, 2016 in Paris.
OPHT: 51.32 (-1.65), PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
GlobeNewswire - Mon May 02, 6:34AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur(TM) for the treatment of chronic non-infectious uveitis of the posterior of the eye (posterior uveitis).
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Wed Apr 27, 8:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after the market close on Thursday, May 5, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
GlobeNewswire - Mon Feb 08, 3:01PM CST
pSivida Corp. (NASDAQ SDV), (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended December 31, 2015.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Mon Feb 01, 11:15AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2016 will be released after the market close on Monday, February 8, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
GlobeNewswire - Thu Jan 28, 9:30AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 18 Annual Bio CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, Monday and Tuesday, February 8 and 9. Dr. Ashton will make his presentation on Tuesday, February 9 at 11 a.m. EST. A webcast of the presentation will be available at the investor relations section of pSivida's website as well as this link: http://www.veracast.com/webcasts/bio/ceoinves...527117.cfm. A replay of the webcast will be available one hour after the conclusion of Dr. Ashton's presentation that day and will be available until May 8, 2016.
ALIM: 1.50 (-0.05), PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Closes $17.8 Million Offering
GlobeNewswire - Wed Jan 13, 6:45AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the closing yesterday of the underwritten public offering of 4,440,000 shares of its common stock at a public offering price of $4.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 440,000 additional shares of common stock, reflecting gross proceeds to pSivida of $17.8 million. pSivida expects net proceeds from the offering to equal approximately $16.4 million after fees and expenses. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), and Northland Securities acted as the joint book-running managers for the offering.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04), LTS: 2.30 (+0.01)

Penn Virginia Corporation Announces Suspension of Trading and Commencement of NYSE Delisting Procedures; Common Stock Expected to Begin Trading on the OTC Pink
GlobeNewswire - Tue Jan 12, 5:02PM CST
Penn Virginia Corporation (NYSE VA) today announced that it received notification from the New York Stock Exchange (NYSE) that the NYSE had determined to commence proceedings to delist the Company's common stock as a result of the NYSE's determination that the Company's common stock was no longer suitable for listing on the NYSE based on "abnormally low" price levels, pursuant to Section 802.01D of the NYSE's Listed Company Manual. The NYSE also suspended trading in the Company's common stock effective immediately.
PVA: 0.15 (-0.04)

pSivida Announces Pricing of $16 Million Public Offering of Common Stock
GlobeNewswire - Thu Jan 07, 7:20AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $4.00 per share, for gross proceeds of $16.0 million. In addition, pSivida has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 440,000 shares of pSivida's common stock.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jan 06, 4:57PM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it intends to offer and sell shares of its common stock in a proposed underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida Plans Medidur(TM) EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
GlobeNewswire - Mon Dec 28, 6:15AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it plans to file for EU marketing approval of Medidur(TM) for chronic non-infectious uveitis of the posterior segment of the eye (posterior uveitis) based on data from a single pivotal trial as a result of the high statistical significance achieved in its first Phase 3 clinical trial. The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) advised pSivida that, consistent with the published Points to Consider (PtC) of the European Agency for Evaluation of Medicinal Products, an application for a product treating a condition like posterior uveitis could be based on statistically compelling and clinically relevant results from just one pivotal trial. The MHRA recently provided this specific advice in formal minutes of a meeting with pSivida held on October 29, 2015 (prior to the Company's receipt of topline results for its first Phase 3 clinical trial). With those results now available, pSivida plans to confirm with the MHRA the plan to file for EU marketing approval of Medidur based on one trial.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

pSivida's Medidur(TM) Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
GlobeNewswire - Tue Dec 22, 6:00AM CST
Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)

With Defaults On the Way, Will Big Oil Go Shopping?
Tyler Crowe and Taylor Muckerman, The Motley Fool - Motley Fool - Wed Nov 18, 1:00PM CST
Oil's low prices have stuck around much longer than so many originally thought. Now, more than a year later, we're starting to see companies like Penn Virginia and Magnum Hunter Resources  buckle under the pressure. On today's episode of ...
APA: 51.29 (+1.50), PVA: 0.15 (-0.04), APC: 56.49 (+2.95)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 30

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 0

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 259

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 0

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 151

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 41

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading

Top 5 Most Recently Viewed Articles

Ripplecoin Mining Unveils Revolutionary Cloud Mining App

Updated Category News Views 160

Introducing the Latest in Cloud Mining Technology Ripplecoin Mining has launched a state-of-the-art mobile application designed to enhance the cloud mining experience for cryptocurrency enthusiasts. Since its inception in 2017, Ripplecoin Mining has positioned itself as a leader in the industry. This exciting update allows users to effortlessly manage their cryptocurrency...

Continue Reading
AMSURG Centers Shine in National Human Experience Awards 2025

Updated Category News Views 108

AMSURG Centers Celebrate National Recognition AMSURG, a distinguished leader in ambulatory surgery center services, is thrilled to announce that three of its esteemed centers have been honored in the latest round of the Human Experience Awards. These awards, conferred by a renowned leader in healthcare experience solutions, aim to recognize organizations across the...

Continue Reading
Wynn Resorts Gains Momentum with Upgraded Growth Outlook

Updated Category News Views 276

Wynn Resorts got a jolt back in 2024 when Morgan Stanley raised its rating from Equal-weight to Overweight, pushing the price target up from $97 to $104. Traders perked up at the mention of a 25% upside, which suggested to many that there was solid potential brewing for those willing to take the plunge. Factors Driving the Upgrade: Opportunity Awaits This upgrade wasn't...

Continue Reading
Innovative Toilet Cleaning Solution for a Fresher Home

Updated Category News Views 117

Introducing the Sani Flush – A Revolution in Toilet Cleaning In the quest for cleaner and more sanitary bathroom experiences, a new invention has emerged. The Sani Flush - Toilet Refresher is designed to transform the way we think about toilet hygiene. Developed by a passionate inventor, this product offers a unique solution for maintaining cleanliness in toilet bowls...

Continue Reading
Understanding the Legal Rights of Fly-E Group Stakeholders

Updated Category News Views 205

Overview of Fly-E Group, Inc. Fly-E Group, Inc. is committed to revolutionizing sustainable transportation through its innovative electric vehicles powered by cutting-edge lithium battery technology. Investors in the company should stay informed about potential legal matters that may affect their investments, especially in light of recent events. Class Action Securities...

Continue Reading